Dapoflit B Tablet contains Dapagliflozin 10mg and Bisoprolol 5mg, a dual-action formulation designed to manage type 2 diabetes along with hypertension, supporting overall cardiovascular and renal health. Its combination ensures better patient compliance by reducing pill burden.
The tablet works by controlling blood glucose levels through Dapagliflozin while Bisoprolol helps regulate blood pressure and cardiac function, providing a synergistic approach for patients with coexisting conditions. Its consistent efficacy makes it a preferred choice among doctors managing complex cardio-metabolic cases.
For suppliers, Dapoflit B Tablet represents a high-demand product in the chronic therapy segment, offering reliable repeat business and strong prescription potential. Its dual-action nature makes it an attractive option for cardiologists, endocrinologists, and general practitioners.
Including Dapoflit B in your portfolio helps distributors expand into the growing market of cardio-metabolic therapy, increase visibility among healthcare providers, and achieve better turnover with a clinically relevant, trusted formulation.